WT1 and neoplasm: This study has therefore explored and compared the following aspects; the immunogenicity of HAGE and WT1 derived ImmunoBody® vaccines individually and in combination in HHDII/DR1 mice, the capacity of the vaccines given individually and in combination to induce activated cytotoxic T cells that can specifically recognise and kill HAGE/WT1-expressing targets in vitro, and finally, the in vivo capability of the combined vaccine to induce tumour rejection using HAGE+/WT1+ expressing humanised B16 cells as a “Proof-of-Concept” in tumour challenge experiments.